Nai-Jung Chiang

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 7

Top Topics

Metastatic Colorectal Cancer

Radiation Therapy

Top Venues

PharmacoEconomics

Cost effectiveness and resource allocation : C/E

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Zi-Rong Chen, Chen-Han Chueh, Nai-Jung Chiang, Yi-Wen Tsai
Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Nai-Jung Chiang, Kien Thiam Tan, Li-Yuan Bai, Chin-Fu Hsiao, Chung-Yu Huang, Yi-Ping Hung, Chien-Jui Huang, San-Chi Chen, Yan-Shen Shan, Yee Chao, Yi-Hsiang Huang, I-Cheng Lee, Pei-Chang Lee, Yung-Yeh Su, Shu-Jen Chen, Chun-Nan Yeh, Li-Tzong Chen, Ming-Huang Chen
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (19) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)